Alovudine
As of the edition of 20 October 2026, Alovudine is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- [18f] Flt Βιοκοσμοσ
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Biokosmos Sa; 3 holders in all
- Registered trials
- 46, 12 stopped early
- Disease areas
- Cancer; Nervous system; Immune system; Urinary and reproductive; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 11 | 8 | 0 | 2 |
| Phase 1 | 19 | 9 | 4 | 5 |
| Phase 2 | 15 | 10 | 1 | 4 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 46 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2004 to now |
| Siemens Molecular Imaging | Lead sponsor of trials | 2007 to now |
| Angiochem | Lead sponsor of trials | 2011 to now |
| Pfizer | Lead sponsor of trials |